Related Experiment Videos
Cancer cell procoagulants and their implications.
1Department of Pathology and Medical Oncology, Colorado Cancer Center, Denver.
Hematology/Oncology Clinics of North America
|December 1, 1992
Summary
Cancer cells disrupt normal blood clotting by altering coagulation factors. This involves both increased procoagulant activity and reduced anticoagulant function, impacting malignant disease progression.
Area of Science:
- Oncology
- Hematology
- Biochemistry
Background:
- Malignant cells are known to influence systemic processes.
- Blood coagulation is a complex system vital for hemostasis.
- Abnormal coagulation is frequently observed in cancer patients.
Purpose of the Study:
- To elucidate the mechanisms by which cancer cells induce abnormal blood coagulation.
- To discuss the roles of specific procoagulant and anticoagulant factors in cancer-associated thrombosis.
- To review the current understanding of coagulation's involvement in malignancy.
Main Methods:
- Literature review and theoretical discussion of known biochemical pathways.
- Analysis of established roles for tissue factor-factor VII and cancer procoagulant.
- Synthesis of current research on coagulation and cancer.
Main Results:
- Cancer cells likely promote hypercoagulability through a dual mechanism.
- Increased levels or activity of procoagulant factors (e.g., tissue factor) contribute to clot formation.
- Deficiencies or reduced function of natural anticoagulant mechanisms are also implicated.
Conclusions:
- Cancer-induced coagulation abnormalities are multifactorial, involving both procoagulant and anticoagulant pathways.
- Factors like tissue factor-factor VII and cancer procoagulant are key players in this process.
- Understanding these interactions is crucial for managing cancer-related complications.